Evidence map›Paper›PMID 38248651›Full record

ArticleMarine drugs2023

Chitotriose Enhanced Antitumor Activity of Doxorubicin through

Heng Li, Ke Ji, Peng Liu, Yan Geng, Jinsong Gong, Chao Zhang, Zhenzhong Ding, Zhenghong Xu, Jinsong Shi

Open access · goldAbstract read
In one paragraph

Article in Marine drugs, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 45% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Heng LiKey Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.ORCID 0000-0002-2386-4587
Ke JiKey Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Peng LiuInstitute of Edible Fungi, Shanghai Academy of Agricultural Sciences, Shanghai 201403, China.
Yan GengKey Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.ORCID 0000-0001-8861-7686
Jinsong GongKey Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Chao ZhangYangzhou Rixing Bio-Tech Co., Ltd., Gaoyou 225601, China.
Zhenzhong DingYangzhou Rixing Bio-Tech Co., Ltd., Gaoyou 225601, China.
Zhenghong XuNational Engineering Laboratory for Cereal Fermentation Technology, Jiangnan University, Wuxi 214122, China.
Jinsong ShiKey Laboratory of Carbohydrate Chemistry and Biotechnology, Ministry of Education, School of Life Sciences and Health Engineering, Jiangnan University, Wuxi 214122, China.
Jiangnan University · CNShanghai Academy of Agricultural Sciences · CN

Funding

National Natural Science Foundation of China 22278181Program for Jiangsu Overseas Visiting Scholar Program for University Prominent Young & Mid-dle-aged Teachers and Presidents none
6 · The paper itself

Abstract

Dietary supplementation is proposed as a strategy to reduce the side effects of conventional chemotherapy for triple-negative breast cancer (TNBC). Chitosan oligosaccharides (COS), a functional carbohydrate, have been identified to potentially inhibit cancer cell proliferation. However, a detailed investigation is required to fully understand its exact influence, particularly in terms of COS composition. The antitumor activities of COS oligomers and its monomer of glucosamine, when combined with doxorubicin separately, were evaluated in MDA-MB-231 cells. Chitotriose was identified to have the most significant synergistic effect. Preincubation with chitotriose was observed to promote the entry of doxorubicin into the cell nuclei and induce morphological changes in the cells. Mechanism analysis at the transcriptional level revealed that the early growth response 1 (

Indexed as

MDA-MB-231 CellsTriple Negative Breast NeoplasmsTrisaccharidesDoxorubicinHumansUp-RegulationchitotrioseDoxorubicinTrisaccharidesantitumor activitychitotrioseearly growth response 1 (Egr1)RNA sequencingtriple-negative breast cancer (TNBC)

Identifiers

PMID38248651
PMCPMC10821154
OpenAlexW4390410675

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.